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Summary  
On October 26, 2015, CDC issued HAN 384 (http://emergency.cdc.gov/han/han00384.asp) that alerted 
(1) public health departments, health care professionals, first responders, and medical examiners and 
coroners of the increase in fentanyl-related unintentional overdose fatalities in multiple states primarily 
driven by illicitly manufactured fentanyl (IMF) (i.e., non-pharmaceutical fentanyl); (2) provided 
recommendations for improving detection of fentanyl-related overdose outbreaks; and (3) encouraged 
states to expand access to naloxone and training for administering naloxone to reduce opioid overdose 
deaths. 
 
The purpose of this HAN update is to alert public health departments, health care professionals, first 
responders, and medical examiners and coroners to new developments that have placed more people at 
risk for fentanyl-involved overdoses from IMF and may increase the risk of non-fatal and fatal overdose. 
These developments include the following: (1) a sharp increase in the availability of counterfeit pills 
containing varying amounts of fentanyl and fentanyl-related compounds (e.g., labeled as Oxycodone, 
Xanax, and Norco), (2) the potential for counterfeit pills containing fentanyl and fentanyl-related 
compounds to be broadly distributed across the United States which could impact states not previously 
impacted by IMF and persons using diverted prescription pills (i.e., licit drugs diverted for illicit purposes 
and involves the diversion of drugs from legal and medically necessary uses towards uses that are illegal 
and typically not medically authorized or necessary)[1], (3) the widening array of toxic fentanyl-related 
compounds being mixed with heroin or sold as heroin, including extremely toxic analogs such as 
carfentanil, and (4) continued increases in the supply and distribution of IMF 
(http://www.cdc.gov/drugoverdose/data/fentanyl-le-reports.html). 
 
Background 
In July 2016, the Drug Enforcement Administration (DEA) issued a nationwide report indicating that 
hundreds of thousands of counterfeit pills have been entering the U.S. drug market since 2014, some 
containing deadly amounts of fentanyl and fentanyl analogs [2]. Traditionally, fentanyl and fentanyl 
analogs in the illicit market have been mixed into heroin or sold as heroin, often without the knowledge of 
the consumer, and have primarily impacted areas where white powder heroin is prevalent, including the 
Northeast, Midwest, and Southeast regions of the United States. The influx of counterfeit pills, which 
closely resemble oxycodone [2,3], Xanax [3], and Norco [4,5], has increased the chance of fentanyl-
involved overdoses among persons misusing prescription opioids or benzodiazepines who seek diverted 
medications on the illicit market [2], in addition to persons who inject, sniff, or snort drugs. Persons who 
misuse prescription pills are geographically widespread; thus, the potential risk for fentanyl overdose has 
spread beyond those regions previously known to be impacted by IMF, and could intensify the impact in 
regions already affected by IMF.  
 
The supply, distribution, and potency of illicitly manufactured fentanyl and fentanyl-related compounds in 
the U.S. drug market is evolving. Carfentanil, an extremely potent fentanyl analog, has been detected in 
at least one state [6,7] and is currently being investigated as a possibility in a few other locations [8]. 
Designed in 1974, carfentanil was previously used exclusively for veterinary use with large animals and is 
not approved for use in humans, as it has been shown to be 100 times more potent than fentanyl in 
animal studies. Other fentanyl-related compounds have been reported by the DEA National Forensic 
Laboratory Information System (NFLIS), which systematically collects drug identification results from drug 
cases submitted for analysis to forensic laboratories (referred to as drug submissions). From 2014 to 
2015 the number of drug submissions testing positive for acetyl fentanyl increased substantially, rising 
from 463 in 2014 to 1,870 in 2015[9,10,11], and in 2016, NFLIS reported increasing drug submissions 
testing positive for furanyl fentanyl (244 drug submissions from January to July 2016) [9]. States should 
be vigilant about the possibility of highly toxic fentanyl-related compounds becoming available in the illicit 
drug market, as well as other highly toxic synthetic opioid derivatives, such as U47700 [2,12]. 
 
NFLIS has reported that the overall supply of illicitly manufactured fentanyl appears to have substantially 
increased from 2014 to 2015, with the number of drug submissions testing positive for illicitly 
manufactured fentanyl doubling during this period (from 5,343 to 13,882). The number of states reporting 
more than 100 fentanyl submissions also increased during this period from 11 to 15 
(http://www.cdc.gov/drugoverdose/data/fentanyl-le-reports.html [9]). Recently, according to NFLIS and 
National Seizure System (NSS) reports, the amount of fentanyl seized in the United States has nearly 
doubled; from October 2014 to September 2015, federal, state, and local law enforcement agencies 
seized a total of 167.7 kilograms of fentanyl, and through June, 2016, they seized 363.8 kilograms of 
fentanyl [9].  
 
Recommendations 
CDC suggests the following actions in response to the increased risk of fentanyl overdose from IMF due 
to the influx of fentanyl-laced counterfeit pills, the widening array of highly toxic fentanyl-related 
compounds, and the continued expansion and geographic spread of the IMF supply: 
 
(1) Improve detection of fentanyl outbreaks to facilitate effective response.  
o Public health departments:  
 Explore methods for rapidly identifying drug overdose outbreaks through use of existing 
surveillance systems such as medical examiner data, emergency medical services data, near-
real time emergency department data, and poison center data [13]. 
 Consider engaging local poison centers to assist with treatment of patients (toll free phone 
number is 800- 222-1222). 
 Track and monitor geographic trends in fentanyl and heroin supply using DEA’s National 
Forensic Laboratory Information System (NFLIS) reports (see NFLIS Report 
http://www.deadiversion.usdoj.gov/nflis/spec_rpt_opioids_2014.pdf). National Heroin Threat 
Assessment Summaries (see NHTA Summary 
https://www.dea.gov/divisions/hq/2016/hq062716_attach.pdf) and alerts on the DEA website [2] 
to inform prevention and response efforts. 
 Raise awareness among key partners and stakeholders to the widening profile of those at risk 
for fentanyl overdose, which increasingly includes persons misusing diverted prescribed oral 
pain and sedative medications [2].  
 Track decedent demographics and known risk factors (e.g., drug type, recent release from an 
institution, previous overdose) to inform prevention efforts [14]. 
 Develop general public health messaging about fentanyl, including fentanyl-laced counterfeit 
pills and fentanyl-related compounds that emphasizes the toxicity and potential lethality of the 
drug versus its high “potency.” The messaging should include warnings of the highly variable 
content of fentanyl present in illicit products, which further elevates risk of overdose [12,15]. 
o Medical examiners and coroners:  
 Screen for fentanyl in suspected opioid overdose cases in regions reporting increases in 
fentanyl seizures, fentanyl-related overdose fatalities, or unusually high spikes in heroin or 
unspecified drug overdose fatalities. 
 Screen specimens using an ELISA test that can detect fentanyl. Confirmatory gas 
chromatography mass spectrometry (GC-MS) of positive screens for fentanyl may either 
confirm the presence of fentanyl or suggest the presence of a fentanyl analog. [16]. When 
fentanyl screening is negative, or confirmatory testing is inconclusive, yet opioid or fentanyl 
overdose is highly suspected, consider specialized testing for fentanyl analogs, particularly if an 
increase in overdoses is occurring.  
o Law Enforcement: Law enforcement plays an important role in identifying and responding to 
increases in the distribution and use of illicitly manufactured fentanyl. 
 Use extreme caution when handling suspected illicitly manufactured fentanyl, white powders, 
and unknown substances (see DEA warning 
https://www.dea.gov/divisions/hq/2016/hq061016.shtml). Use appropriate safety precautions 
and personal protective equipment (see NIOSH Emergency Response Card 
http://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750022.html) 
 Prioritize and expedite laboratory testing of drug samples taken from drug overdose scenes, if 
possible. 
 Share data on fentanyl and fentanyl analog drug seizures with local health departments, 
medical examiners, and coroners. 
 Carry a supply of naloxone so that it can be administered immediately to mitigate the effects of 
the overdose. (See Recommendation 2 below.) 
o Laboratories: The following government forensic laboratories supporting law enforcement can 
provide assistance with reference materials or reference data on a case-by-case basis. 
 DEA Reference Materials Program- DEALabRefMaterials@usdoj.gov 
 DEA Emerging Trends Program- DEA.Emerging.Trends@usdoj.gov 
 Scientific Working Group for the Analysis of Seized Drugs - SWGDRUG.ORG  
 
(2)  Expand Use of Naloxone and Treatment 
o Health Care Providers:  
 Multiple dosages of naloxone may need to be administered per overdose event, because of 
fentanyl’s increased potency relative to other opioids. Orally-ingested counterfeit pills laced with 
fentanyl may require prolonged dosing of naloxone in the ED/hospital setting due to a delayed 
toxicity that has been reported in some cases [15]. 
 Facilitate access to Medication-Assisted Treatment (MAT). MAT is a comprehensive approach 
to addressing the needs of persons with opioid use disorders that combines the use of 
medication with counseling and behavioral therapies.  Providers should discuss treatment 
options with persons who have an opioid use disorder, and persons who have experienced an 
opioid-related overdose once they are stabilized. 
o Harm reduction organizations:  
 Expand naloxone access to persons at risk for opioid-related overdose and to their friends and 
family members [17].  
 Train those using drugs how to effectively administer naloxone and emphasize the importance 
of calling 911 immediately after recognition of an overdose, because naloxone that is available 
in the field may be insufficient to reverse the overdose.  
 
For more information 
 CDC Health Advisory: Recommendations for Laboratory Testing for Acetyl Fentanyl and Patient 
Evaluation and Treatment for Overdose with Synthetic Opioid at 
http://emergency.cdc.gov/han/han00350.asp  
 Canadian Centre on Substance Abuse Bulletin: Novel Synthetic Opioids in Counterfeit 
Pharmaceuticals and Other Illicit Street Drugs at (see CCENDU Bulletin 
http://www.ccsa.ca/Resource%20Library/CCSA-CCENDU-Novel-Synthetic-Opioids-Bulletin-2016-
en.pdf).  
 MMWR: Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid–Involved 
Overdose Deaths — 27 States, 2013–2014 
http://www.cdc.gov/mmwr/volumes/65/wr/mm6533a2.htm?s_cid=mm6533a2_w 
 MMWR: Increase in Fentanyl-Related Overdose Deaths — Ohio and Florida, 2010-2015 
http://www.cdc.gov/mmwr/volumes/65/wr/mm6533a3.htm?s_cid=mm6533a3_w  
 SAMHSA Opioid Overdose Toolkit at: http://store.samhsa.gov/shin/content/SMA13-
4742/Overdose_Toolkit_2014_Jan.pdf  
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The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national, and international 
organizations. 
 
____________________________________________________________________________________ 
Categories of Health Alert Network messages:  
Health Alert  Requires immediate action or attention; highest level of importance 
Health Advisory May not require immediate action; provides important information for a specific incident or situation 
Health Update  Unlikely to require immediate action; provides updated information regarding an incident or situation 
HAN Info Service Does not require immediate action; provides general public health information 
  
##This message was distributed to state and local health officers, state and local epidemiologists, state 
and local laboratory directors, public information officers, epidemiologists, HAN coordinators, and clinician 
organizations## 
 
